12th December 2007 -Antitope Ltd. today announced a research collaboration with UCB Celltech (“UCB”) where Antitope will apply EpiScreenTM technology to profile the immunogenicity of therapeutic monoclonal antibodies. “We are very pleased to be working with UCB whom we recognize as a world-class company in the development and commercialization of therapeutic antibodies” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. “We look forward to assisting UCB in selecting therapeutic antibodies with a low potential for immunogenicity.”
